

Attentional functioning in patients with posttraumatic stress disorder: a preliminary study

Michael David Horner,^{1*} Jacobo E. Mintzer,¹ Travis H. Turner,¹ Keith R. Edmiston,² and Olga Brawman-Mintzer¹

¹ Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, South Carolina, USA; Medical University of South Carolina, Charleston, South Carolina, USA

² College of Charleston, Charleston, South Carolina, USA

Objective. To compare patients with posttraumatic stress disorder (PTSD) to patients without psychiatric or cognitive disorders on neuropsychological measures of attention.

Methods. The sample included 19 patients with PTSD and 22 participants with no cognitive or psychiatric diagnosis. All had been referred for clinical neuropsychological evaluation at a VA Medical Center. None were diagnosed with dementia, delirium, or current substance dependence except nicotine or caffeine, and none had a history of stroke or of traumatic brain injury with loss of consciousness. Patients were excluded if they failed to exert adequate effort on testing.

Results. PTSD patients performed significantly more poorly than patients without psychiatric diagnoses on Digit Span.

Conclusion. PTSD patients were impaired relative to participants without psychiatric diagnoses on a measure of focused attention. Several factors, including the small sample size, suggest that the results should be considered preliminary.

Received 21 September 2012; Accepted 20 November 2012

Keywords: PTSD, neuropsychology, attention, cognition.

Recent years have seen an increase in the study of cognitive difficulties associated with posttraumatic stress disorder (PTSD). A meta-analysis¹ found that PTSD was associated with decrements in memory, particularly for verbal information, but that effect sizes were small to moderate. The question of whether these cognitive deficits represent premorbid risk factors for PTSD, effects of PTSD, or both has yet to be definitively determined.^{1,2}

An earlier review³ noted that no studies at that time had systematically evaluated effort on neuropsychological examination, even though over-reporting of psychiatric symptomatology and impairment has been reported in certain subsets of PTSD patients.^{4,5} Thus, inclusion of PTSD patients who were exerting sub-optimal effort could have exaggerated findings of impairment. Other factors, such as substance abuse and other psychiatric comorbidity, had also not been consistently controlled in many studies. These factors

continue to be significant potential confounds in many of the studies included in Brewin *et al.*'s¹ meta-analysis.

Several of the studies since Horner and Hamner's³ earlier review have reported decrements in attention and memory among combat veterans with PTSD.^{6–10} Other studies have reported deficits in a broad range of cognitive functions in individuals with non-combat-related PTSD.^{11–15} There is also evidence that veterans with PTSD are at higher risk of later developing dementia.¹⁶ However, some studies have produced essentially negative findings when controlling for various potential confounds.^{17–21}

Thus, despite continuing, active research in this area, fundamental questions remain about whether specific neuropsychological deficits are associated with PTSD. Furthermore, only two studies to date^{7,21} have systematically examined whether patients were exerting adequate effort on cognitive tests. The present study attempted to address some of the methodological confounds in previous studies by excluding patients who failed formal tests of effort, or who had various other potentially confounding comorbidities. As several previous studies^{6–9} had reported attentional impairment in PTSD patients, and as difficulty concentrating actually constitutes one of the diagnostic

*Address for correspondence: Michael David Horner, PhD, Mental Health Service (116), Ralph H. Johnson VA Medical Center, 109 Bee St., Charleston, SC 29401, USA.
(Email: hornermd@musc.edu)

This study was supported in part by the Department of Veterans Affairs.

criteria for PTSD,²² we specifically examined attentional functioning in these patients. We hypothesized that patients with PTSD would perform more poorly than patients without psychiatric disorders on standard tests of attention.

Methods

This study was approved by the Institutional Review Board of the Medical University of South Carolina, and by the Research and Development Service of the Ralph H. Johnson Department of Veterans Affairs Medical Center.

Participants

Data were drawn from an initial sample of consecutive patients referred from Primary Care, Neurology, Mental Health and other VA clinics for neuropsychological evaluation in a VA Medical Center's Neuropsychology Clinic. Referrals were typically made because of concerns on the part of the patient, family member, or healthcare provider about cognitive difficulties.

Patients were included in the study only if their effort during testing had been formally assessed and found to be adequate. Effort was determined *at the time of clinical examination* using the Test of Memory Malingering (TOMM)²³ and/or Word Memory Test (WMT).²⁴ In addition, due to a policy implemented in 2003, nearly all patients were administered the Rey Fifteen-Item Test (RFIT),²⁵ and, due to a policy implemented in 2005, nearly all patients were also administered the Recognition Trial of this test.²⁶ Standard cutoffs were used for each effort test (for TOMM, Trial 2 and Retention Trial ≥ 45 ; for WMT, Immediate Recall, Delayed Recall, and Consistency $> 90\%$; for RFIT, recall > 8 and [recall + hits - false positives] ≥ 20). Other clinical indicators of effort were also used, including impairment on formal tests that was grossly disproportional to the patient's observed or reported functional abilities, notably unusual errors or patterns of performance, and other behaviors that were strongly suggestive of suboptimal effort. In general, patients who scored below the standard cutoff on at least one effort index and who demonstrated other such indications of poor effort were excluded from the study.

Psychiatric diagnoses were made by the neuropsychologist at the time of clinical examination based on patients' current symptomatology, using standard DSM-IV criteria.²² Thus, all patients in the PTSD group met full diagnostic criteria for that disorder. Patients were excluded from the study if any of the following conditions were present: (1) diagnosis, based on the neuropsychological examination, of dementia, delirium, or current dependence on alcohol or other

drug except nicotine or caffeine; (2) history of cerebrovascular accident; (3) history of traumatic brain injury with loss of consciousness.

Of the remaining sample, patients who were diagnosed in the examination with PTSD (with or without comorbid psychiatric diagnosis) comprised the "PTSD" group. In light of the study hypotheses, two patients were excluded from the PTSD group because of psychiatric comorbidities known to affect attentional functioning: one with attention-deficit/hyperactivity disorder and one with schizoaffective disorder. In the final sample, there were 19 patients in the PTSD group. Comorbid psychiatric diagnoses in this group included major depressive disorder ($N = 7$), generalized anxiety disorder ($N = 1$), borderline personality disorder ($N = 1$), and obsessive-compulsive personality disorder ($N = 1$).

A second subset of patients was identified who, based on the neuropsychological examination, were not diagnosed with any psychiatric or cognitive disorder; these comprised the "No Diagnosis" group. While not necessarily healthy controls, these were individuals who had been referred for neuropsychological evaluation for complaints generally similar to those in the PTSD group, but who were found not to have significant psychopathology or cognitive impairment. In the final sample, there were 22 patients in the No Diagnosis group.

Neuropsychological test batteries had been individualized for each patient in the course of clinical evaluation. Thus, a subset of neuropsychological tests (see below) was identified that was sensitive to attentional dysfunction, and that had been administered to an adequate number of patients in each group.

Procedures

All neuropsychological tests were administered and scored according to their test manuals, as part of routine neuropsychological evaluation. Raw scores were used for all analyses. The attentional tests examined in this study were those that had been administered to all patients in each of the two groups, in the course of routine clinical evaluation. These tests were as follows:

- *Digit Span subtest of Wechsler Memory Scale, third edition (WMS-III)*²⁷: This is an attentional test in which participants repeat auditorily presented strings of numbers forward and backward.
- *Mental Control subtest of WMS-III*²⁷: This is an attentional test consisting of timed items in which participants recite overlearned information forward or backward.
- *Trail Making Test*²⁸: In Part A, which is sensitive to difficulties in attention and information-processing speed, participants connect numbers on a page

Table 1. Mean (SD) demographic characteristics and raw scores on neuropsychological tests of the two patient groups

Test	PTSD (N = 19)	No psychiatric diagnosis (N = 22)
Age	44.0 (12.9)	51.3 (17.6)
Years of education	13.5 (3.0)	13.1 (2.9)
Male (N)	16	20
Race (N):		
African American	7	2
Caucasian	9	19
Other	3	1
Digit Span*	13.8 (3.0)	16.2 (3.5)
Mental Control	21.4 (4.4)	23.9 (5.9)
Trail Making Test, Part A	37.2 (16.5)	34.7 (11.6)
Trail Making Test, Part B	107.3 (46.7)	84.9 (39.0)

* $p \leq .05$.

sequentially. In Part B, which is additionally sensitive to executive dysfunction, participants alternate between numbers and letters.


Results

As shown in Table 1, the groups did not differ significantly in age or level of education. Group performance on cognitive tests was compared using a series of t-tests, as the small sample size did not permit use of MANOVA. Patients with PTSD performed significantly more poorly than patients with no diagnosis on Digit Span ($t = -2.38$, $p < .05$). PTSD patients also performed slightly more poorly on the other tests, but no other group differences were significant. The effect size for group difference on Digit Span was estimated to be within the medium range (Cohen's $d = .59$).

To explore whether Digit Span performances in patient groups were deficient relative to the general healthy population, raw scores from individual patients were converted to age-adjusted percentiles according to procedures described in the test manual. Boxplots of percentile ranks, with median percentile illustrated with a black line and whiskers set to 1.5 times the interquartile range, are shown in Figure 1. The median score in the PTSD group (24th percentile) fell within the low average range, while the median score in the No Diagnosis group fell in the average range, according to standard qualitative guidelines for interpretation.²⁹ The distribution of performances observed in PTSD patients was also found to be restricted relative to the comparison group.

Discussion

In this clinical sample of patients exerting valid effort on neuropsychological examination, patients

**Figure 1.** Percentile ranks on Digit Span subtest of the Wechsler Memory Scale, Third Edition (WMS-III) by group.

diagnosed with PTSD performed more poorly than those who were not assigned a cognitive or psychiatric diagnosis on one measure of focused attention. To our knowledge, among previous neuropsychological studies of PTSD patients, very few^{7,21} have reported the use of symptom validity tests to ensure the validity of cognitive data. Demakis *et al.*²¹ noted that the existing literature on cognition in PTSD is probably contaminated by invalid data produced by patients who were not motivated to exert maximal effort on examination. Across clinical settings, up to 39% of patients with various diagnoses may fail to exert adequate effort on cognitive testing.³⁰ Thus, we believe that the present study is one of the first to demonstrate selective attentional impairment in PTSD patients, compared to individuals without psychiatric diagnoses, even when participants exerting suboptimal effort were excluded from the analyses.

Several aspects of the present study indicate that the results should be considered very preliminary. As patients were typically referred for neuropsychological evaluation because of cognitive complaints, it is quite possible that the present findings would not generalize to PTSD patients as a whole (e.g., those without significant cognitive complaints). Thus, attentional dysfunction might not be present in all, or even most, patients with PTSD. But the present results do suggest that such dysfunction is present in at least a subset of PTSD patients, and that it is not easily attributable to various other confounding factors such as history of traumatic brain injury (TBI), current substance abuse, or inadequate effort during cognitive testing.

The small sample size further indicates that the present results should be interpreted cautiously. Replication in a larger sample, perhaps including PTSD patients with and without cognitive complaints, will be important. Similarly, the demographic composition of

the two groups was not identical. While the mean age of the PTSD patients was somewhat lower than that of the other group, this difference was not statistically significant. Also, while a clear relationship between racial background and attentional functioning has not been established, the patients with PTSD included fewer Caucasians and more African Americans than the comparison group. Thus, while these demographic factors would not be expected to affect the present findings, it will be important to match groups more closely in future studies.

It is possible that the use of the TOMM with some patients, rather than potentially more sensitive effort tests such as the Word Memory Test, might have led to the inclusion of patients who were not actually exerting adequate effort on cognitive tests. Future studies could thus consistently include stringent measures of effort. Finally, the present findings, even if replicable, might not be specific to PTSD; it is possible that mild attentional decrement is present in, e.g., other anxiety disorders also.

The mechanism by which PTSD would be associated with attentional decrement remains unclear, and would merit future investigation if the present findings are replicated in larger samples. In addition, to help clarify whether the present findings might pertain to PTSD patients more generally, future studies could compare PTSD patients who have cognitive complaints and who are referred for neuropsychological evaluation to PTSD patients who have not been referred. More definitive results could also be obtained by using comparison groups of trauma-exposed individuals who have not developed PTSD. Finally, future studies could assess attentional functioning in PTSD patients before and after PTSD treatment, to determine whether reduction of PTSD symptoms might similarly improve attention.

Conclusions

While the present results must be considered preliminary, they suggest some attentional decrement in patients diagnosed with PTSD compared to patients who are without psychiatric or cognitive disorders. Future studies are needed to elucidate the nature and mechanism of this decrement.

Disclaimer

The contents of this manuscript do not represent the views of the Department of Veterans Affairs or the United States Government.

Disclosures

Jacobo Mintzer has the following disclosures: Pfizer: research support (grant); NIH/NIA: research support

(grant); Genentech: research support (grant); University of San Diego: research support (grant); Novartis, Inc.: research support (grant); Janssen: research support (grant); Wyeth, Inc.: research support (grant); Lilly Research Labs: research support (grant); Eli Lilly & Company: research support (grant); CSP #545: research support (grant); Elan Pharmaceuticals: research support (grant); BioPharma Connex: founder and chair (salary); NeuroQuest: consultant. Olga Brawman-Mintzer has the following disclosures: Takeda: research support (grant); Shire: research support (grant); Novartis: research support (grant). The remaining authors have nothing to disclose.

References

1. Brewin CR, Kleiner JS, Vasterling JJ, Field AP. Memory for emotionally neutral information in posttraumatic stress disorder: a meta-analytic investigation. *J Abnorm Psychol.* 2007; **116**(3): 448–463.
2. Vasterling JJ, Verfaellie M. Posttraumatic stress disorder: a neurocognitive perspective. *J Int Neuropsychol Soc.* 2009; **15**(6): 826–829.
3. Horner MD, Hamner MB. Neurocognitive functioning in posttraumatic stress disorder. *Neuropsychol Rev.* 2002; **12**(1): 15–30.
4. Frueh BC, Gold PB, de Arellano MA. Symptom overreporting in combat veterans evaluated for PTSD: differentiation on the basis of compensation seeking status. *J Pers Assess.* 1997; **68**: 369–384.
5. Frueh BC, Hamner MB, Cahill SP, Gold PB, Hamlin KL. Apparent symptom overreporting in combat veterans evaluated for PTSD. *Clin Psychol Rev.* 2000; **20**: 853–885.
6. Gilbertson MW, Gurvits TV, Lasko NB, Orr SP, Pitman RK. Multivariate assessment of explicit memory function in combat veterans with posttraumatic stress disorder. *J Trauma Stress.* 2001; **14**(2): 413–432.
7. Marx BP, Brailey K, Proctor SP, et al. Association of time since deployment, combat intensity, and posttraumatic stress symptoms with neuropsychological outcomes following Iraq war deployment. *Arch Gen Psychiatry.* 2009; **66**(9): 996–1004.
8. Samuelson KW, Neylan TC, Metzler TJ, et al. Neuropsychological functioning in posttraumatic stress disorder and alcohol abuse. *Neuropsychology.* 2006; **20**(6): 716–726.
9. Vasterling JJ, Duke LM, Brailey K, et al. Attention, learning, and memory performances and intellectual resources in Vietnam veterans: PTSD and no disorder comparisons. *Neuropsychology.* 2002; **16**(1): 5–14.
10. Woodward SH, Kaloupek DG, Grande LJ, et al. Hippocampal volume and declarative memory function in combat-related PTSD. *J Int Neuropsychol Soc.* 2009; **15**(6): 830–839.
11. Eren-Kocak E, Kilic C, Aydin I, Hizli FG. Memory and prefrontal functions in earthquake survivors: differences between current and past post-traumatic stress disorder patients. *Acta Psychiatr Scand.* 2009; **119**: 35–44.

12. Hart J, Kimbrell T, Fauver P, et al. Cognitive dysfunctions associated with PTSD: evidence from World War II prisoners of war. *J Neuropsychiatry Clin Neurosci.* 2008; **20**(3): 309–316.
13. Kanagaratnam P, Asbjornsen AE. Executive deficits in chronic PTSD related to political violence. *J Anxiety Disord.* 2007; **21**: 510–525.
14. Leskin LP, White PM. Attentional networks reveal executive function deficits in posttraumatic stress disorder. *Neuropsychology.* 2007; **21**(3): 275–284.
15. Twamley EW, Allard CB, Thorp SR, et al. Cognitive impairment and functioning in PTSD related to intimate partner violence. *J Int Neuropsychol Soc.* 2009; **15**(6): 879–887.
16. Yaffe K, Vittinghoff E, Lindquist K, et al. Post-traumatic stress disorder and risk of dementia among U.S. veterans. Paper presented at: Alzheimer's Association International Conference on Alzheimer's Disease (ICAD); July 11–16, 2009; Vienna, Austria.
17. Brandes D, Ben-Schachar G, Gilboa A, et al. PTSD symptoms and cognitive performance in recent trauma survivors. *Psychiatry Res.* 2002; **110**(3): 231–238.
18. Crowell TA, Kieffer KM, Siders CA, Vanderploeg RD. Neuropsychological findings in combat-related posttraumatic stress disorder. *Clin Neuropsychol.* 2002; **16**(3): 310–321.
19. Neylan TC, Lenoci M, Rothlind J, et al. Attention, learning, and memory in posttraumatic stress disorder. *J Trauma Stress.* 2004; **17**(1): 41–46.
20. Stein MB, Kennedy CM, Twamley EW. Neuropsychological function in female victims of intimate partner violence with and without posttraumatic stress disorder. *Biol Psychiatry.* 2002; **52**(11): 1079–1088.
21. Demakis GJ, Gervais RO, Rohling ML. The effect of failure on cognitive and psychological symptom validity tests in litigants with symptoms of post-traumatic stress disorder. *Clin Neuropsychol.* 2008; **22**(5): 879–895.
22. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*, 4th ed, text revision (DSM-IV-TR) Washington, DC: American Psychiatric Association; 2000.
23. Tombaugh TN. *Test of Memory Malingering (TOMM) <annual.* North Tonawanda, NY: Multi-Health Systems, Inc.; 1996.
24. Green P. *Word Memory Test Manual for Windows: User's Manual.* Edmonton, AB, Canada: Green's Publishing; 2003.
25. Strauss E, Sherman EMS, Spreen O. *A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary*, 3rd ed. New York: Oxford University Press; 2006.
26. Boone KB, Salazar X, Lu P, Warner-Chacon K, Razani J. The Rey 15-Item Recognition Trial: a technique to enhance sensitivity of the Rey 15-Item Memorization Test. *J. C. Exp. Neuropsychol.* 2002; **24**(5): 561–573.
27. Wechsler D. *Wechsler Memory Scale*, 3rd ed. (WMS-III). San Antonio, TX: The Psychological Corporation, Harcourt Brace & Company; 1997.
28. Reitan RM, Wolfson D. *The Halstead-Reitan Neuropsychological Test Battery.* Tucson, AZ: Neuropsychology Press; 1985.
29. Lezak MD, Howieson DB, Loring DW. *Neuropsychological Assessment*, 4th ed. New York: Oxford University Press; 2004.
30. Mittenberg W, Patton C, Canyock EM, Condit DC. Base rates of malingering and symptom exaggeration. *J. C. Exp. Neuropsychol.* 2002; **24**(8): 1094–1102.